Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1994 Jul;49(7):652–656. doi: 10.1136/thx.49.7.652

Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group.

H A Kerstjens 1, D S Postma 1, J J van Doormaal 1, A K van Zanten 1, P L Brand 1, P N Dekhuijzen 1, G H Koëter 1
PMCID: PMC475051  PMID: 8066559

Abstract

BACKGROUND--Recent reports have suggested short-term changes in serum parameters of bone metabolism with inhaled corticosteroids. The relevance of these findings to the balance between bone formation and resorption during years of corticosteroid treatment remains uncertain. METHODS--Two novel markers of bone turnover were first compared with conventional markers in a pilot study and subsequently measured in a long-term double blind study of inhaled corticosteroids. In study I 15 patients were newly started on at least 800 micrograms inhaled corticosteroids daily. At entry and after four weeks serum levels of alkaline phosphatase, osteocalcin, and PICP (procollagen type I carboxy terminal propeptide; a procollagen splice product) were measured as markers of bone formation, as well as the urinary hydroxyproline/creatinine ratio and serum levels of ICTP (type I collagen carboxy terminal telopeptide; a collagen degradation product) as markers of bone resorption. In study II 70 patients with airways obstruction received 800 micrograms beclomethasone daily in addition to terbutaline and 85 received bronchodilators only in a double blind fashion. Serum levels of PICP and ICTP were measured before and after 2.5 years of treatment. RESULTS--In study I a decrease in osteocalcin levels was accompanied by an increase in levels of PICP and a small and non-significant rise in alkaline phosphatase. There were no changes in hydroxyproline or ICTP. In study II no differences were found in serum levels of PICP between the treatment groups; an increase in serum ICTP was found in the group treated without inhaled corticosteroids compared with the group treated with inhaled corticosteroids. CONCLUSIONS--No detrimental long-term effect of inhaled corticosteroids was found with three conventional and two novel parameters of bone metabolism. The results indicate that long-term changes in bone turnover during treatment with inhaled corticosteroids should not be deduced from short-term studies with single serum parameters of bone metabolism, but well designed long-term studies of, for example, bone densitometry should be awaited before quoting detrimental effects of inhaled corticosteroids on bone metabolism.

Full text

PDF
652

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali N. J., Capewell S., Ward M. J. Bone turnover during high dose inhaled corticosteroid treatment. Thorax. 1991 Mar;46(3):160–164. doi: 10.1136/thx.46.3.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Delmas P. D. Biochemical markers of bone turnover: methodology and clinical use in osteoporosis. Am J Med. 1991 Nov 25;91(5B):59S–63S. doi: 10.1016/0002-9343(91)90250-2. [DOI] [PubMed] [Google Scholar]
  3. Elomaa I., Virkkunen P., Risteli L., Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer. 1992 Aug;66(2):337–341. doi: 10.1038/bjc.1992.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eriksen E. F., Charles P., Melsen F., Mosekilde L., Risteli L., Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res. 1993 Feb;8(2):127–132. doi: 10.1002/jbmr.5650080202. [DOI] [PubMed] [Google Scholar]
  5. Glowacki J., Lian J. B. Impaired recruitment and differentiation of osteoclast progenitors by osteocalcin-deplete bone implants. Cell Differ. 1987 Sep;21(4):247–254. doi: 10.1016/0045-6039(87)90479-9. [DOI] [PubMed] [Google Scholar]
  6. Gundberg C. M., Weinstein R. S. Multiple immunoreactive forms of osteocalcin in uremic serum. J Clin Invest. 1986 Jun;77(6):1762–1767. doi: 10.1172/JCI112499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Haahtela T., Järvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., Nikander K., Persson T., Reinikainen K., Selroos O. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388–392. doi: 10.1056/NEJM199108083250603. [DOI] [PubMed] [Google Scholar]
  8. Juniper E. F., Kline P. A., Vanzieleghem M. A., Ramsdale E. H., O'Byrne P. M., Hargreave F. E. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990 Oct;142(4):832–836. doi: 10.1164/ajrccm/142.4.832. [DOI] [PubMed] [Google Scholar]
  9. Kerstjens H. A., Brand P. L., Hughes M. D., Robinson N. J., Postma D. S., Sluiter H. J., Bleecker E. R., Dekhuijzen P. N., de Jong P. M., Mengelers H. J. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med. 1992 Nov 12;327(20):1413–1419. doi: 10.1056/NEJM199211123272003. [DOI] [PubMed] [Google Scholar]
  10. Lian J. B., Tassinari M., Glowacki J. Resorption of implanted bone prepared from normal and warfarin-treated rats. J Clin Invest. 1984 Apr;73(4):1223–1226. doi: 10.1172/JCI111308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Melkko J., Niemi S., Risteli L., Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990 Jul;36(7):1328–1332. [PubMed] [Google Scholar]
  12. Oikarinen A., Autio P., Vuori J., Vänänen K., Risteli L., Kiistala U., Risteli J. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br J Dermatol. 1992 Feb;126(2):172–178. doi: 10.1111/j.1365-2133.1992.tb07816.x. [DOI] [PubMed] [Google Scholar]
  13. Packe G. E., Douglas J. G., McDonald A. F., Robins S. P., Reid D. M. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax. 1992 Jun;47(6):414–417. doi: 10.1136/thx.47.6.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Parfitt A. M., Simon L. S., Villanueva A. R., Krane S. M. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res. 1987 Oct;2(5):427–436. doi: 10.1002/jbmr.5650020510. [DOI] [PubMed] [Google Scholar]
  15. Pouw E. M., Prummel M. F., Oosting H., Roos C. M., Endert E. Beclomethasone inhalation decreases serum osteocalcin concentrations. BMJ. 1991 Mar 16;302(6777):627–628. doi: 10.1136/bmj.302.6777.627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Power M. J., Fottrell P. F. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci. 1991;28(4):287–335. doi: 10.3109/10408369109106867. [DOI] [PubMed] [Google Scholar]
  17. Reid I. R. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol (Oxf) 1989 Jan;30(1):83–103. doi: 10.1111/j.1365-2265.1989.tb03730.x. [DOI] [PubMed] [Google Scholar]
  18. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed] [Google Scholar]
  19. Szulc P., Chapuy M. C., Meunier P. J., Delmas P. D. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest. 1993 Apr;91(4):1769–1774. doi: 10.1172/JCI116387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Toogood J. H. Complications of topical steroid therapy for asthma. Am Rev Respir Dis. 1990 Feb;141(2 Pt 2):S89–S96. [PubMed] [Google Scholar]
  21. Toogood J. H., Jennings B., Hodsman A. B., Baskerville J., Fraher L. J. Effects of dose and dosing schedule of inhaled budesonide on bone turnover. J Allergy Clin Immunol. 1991 Oct;88(4):572–580. doi: 10.1016/0091-6749(91)90150-m. [DOI] [PubMed] [Google Scholar]
  22. Wolthers O. D., Pedersen S. Growth of asthmatic children during treatment with budesonide: a double blind trial. BMJ. 1991 Jul 20;303(6795):163–165. doi: 10.1136/bmj.303.6795.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. van der Wiel H. E., Lips P., Nauta J., Netelenbos J. C., Hazenberg G. J. Biochemical parameters of bone turnover during ten days of bed rest and subsequent mobilization. Bone Miner. 1991 May;13(2):123–129. doi: 10.1016/0169-6009(91)90079-f. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES